Skip to main content
. 2021 Nov 11;326(20):2031–2042. doi: 10.1001/jama.2021.19569

Figure 2. Cumulative Incidence Estimates (Kaplan-Meier) for 2 Composite End Points in the Overlap-Weighted Analysis.

Figure 2.

HR indicates hazard ratio. The date of bariatric surgery and liver biopsy was considered as the index date for patients in the bariatric surgery group. The date of first liver biopsy on which all selection criteria were met served as the index date for patients in the nonsurgical control group.

aComposite end point that was defined as the first occurrence of progression to clinical or histological cirrhosis, development of hepatocellular carcinoma, liver transplantation, or liver-related mortality after the index date. The median observation time was 84.6 months (IQR, 37.1-118.5 months) in the bariatric surgery group and 85.3 months (IQR, 48.5-127.4 months) in the nonsurgical control group.

bComposite end point that was defined as the first occurrence of coronary artery events, cerebrovascular events, heart failure, or cardiovascular mortality after the index date. The median observation time was 81.6 months (IQR, 34.9-116.0 months) in the bariatric surgery group and 80.6 months (IQR, 46.2-126.1 months) in the nonsurgical control group.